<DOC>
	<DOCNO>NCT00004201</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness gemcitabine plus carboplatin gemcitabine plus cisplatin treating patient stage IIIB , stage IV , recurrent non-small cell lung cancer .</brief_summary>
	<brief_title>Gemcitabine Plus Carboplatin Cisplatin Treating Patients With Stage IIIB , Stage IV , Recurrent Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate gemcitabine carboplatin vs gemcitabine cisplatin patient stage IIIB , IV , recurrent non-small cell lung cancer . II . Determine toxicity two regimen patient population . III . Determine time progression one year survival patient regimens . OUTLINE : This randomize study . Patients stratified stage disease gender . Patients randomize one two treatment arm . Arm I : Patients receive gemcitabine IV 30 minute day 1 8 , follow carboplatin 60 minute day 1 . Arm II : Patients receive gemcitabine IV 30 minute day 1 8 , follow cisplatin IV 60 minute day 1 . Treatment repeat every 3 week 8 course absence disease progression unacceptable toxicity . Patients follow monthly 3 month , every two month 6 month , every 3 month thereafter . PROJECTED ACCRUAL : A total 80 patient ( 40 per treatment arm ) accrue study within 1 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IIIB IV nonsmall cell lung cancer ( NSCLC ) Recurrent NSCLC treat radiation surgery allow Bidimensionally measurable disease xray , CT scan , MRI , physical exam outside irradiation field No active CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 12 week Hematopoietic : WBC least 3,500/mm3 Granulocyte count great 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hematocrit least 30 % Hepatic : Bilirubin great 2 mg/dL PT aPTT great 1.5 time upper limit normal ( ULN ) AST ALT great 3 time ULN ( 5 time ULN liver metastasis present ) Renal : Creatinine great 2 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception 3 month study No serious concurrent systemic disorder would preclude study compliance No active infection No second primary malignancy within past 5 year , except : Adequately treat basal cell skin cancer Carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic therapy No concurrent immunotherapy Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 3 week since prior endocrine therapy No concurrent hormonal therapy ( except contraceptive replacement steroid ) Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics Other : At least 4 week since prior investigational drug No concurrent experimental drug No concurrent interleukin11 patient cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>